Skip to main content
Clinical Trials/NCT04355741
NCT04355741
Completed
Not Applicable

Gut Microbiota, "Spark and Flame" of COVID-19 Disease

Universidade Nova de Lisboa3 sites in 1 country115 target enrollmentApril 20, 2020
ConditionsCOVID-19

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COVID-19
Sponsor
Universidade Nova de Lisboa
Enrollment
115
Locations
3
Primary Endpoint
Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Elderly, hypertension, diabetes and cardiovascular diseases are risk factors for COVID-19 morbility and mortality. However, the real reason for this is not yet understood. It is well documented that gut microbiota has a critical role in health, particularly in the immune system and therefore, we propose that gut microbiota composition could affect vulnerability and disease outcomes of COVID-19.

Detailed Description

In order to explore this hypothesis, we will analyse the gut microbiota of SARSCoV-2 infected patients categorized according to location: \[1\] ambulatory (self-isolation at home), \[2\] ward and \[1\] ICU; and severity.

Registry
clinicaltrials.gov
Start Date
April 20, 2020
End Date
July 16, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adults of 18 years and above.
  • COVID-19 patients.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.

Time Frame: Stool samples of COVID-19 patients will be collected after subject enrollment (single point collection)

Secondary Outcomes

  • Differences in gut microbiota composition between COVID-19 patients in relation to mortality.(Through study completion, an average of 3 months.)
  • Differences in gut microbiota composition between COVID-19 patients in relation to length of stay in hospitals.(Through study completion, an average of 3 months.)
  • Differences in gut microbiota composition between COVID-19 patients in relation to duration of mechanical ventilation.(Through study completion, an average of 3 months.)

Study Sites (3)

Loading locations...

Similar Trials